Clinical trial · Interventional
Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC
Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC: A Phase Ib Study,Open-label,Dose-expansion Study
NCT02929290CI-TRIAL-00053842unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics of BPI-9016M in patients with c-Met-dysregulated advanced NSCLC. Biomarkers related to the efficacy of BPI-9016M will be investigated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BPI-9016M | Drug | AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BPI-9016M
- description
- Part I:Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort. Part II:400mg BPI-9016M Tablet will be administered orally to patients twice a day.
- interventionNames
- Drug: BPI-9016M
Primary outcomes (3)
- measure
- Participants with Adverse Events
- timeFrame
- 18 months
- measure
- Objective Response Rate
- timeFrame
- 16 weeks
- measure
- Disease Control Rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed, locally advanced or metastatic NSCLC patients, who is not suitable for surgery or radiotherapy * Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors(RECIST1.1) * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Life expectancy ≥12 weeks * Must have evidence of positive c-Met protein expression by IHC from either local data or the results of molecular pre-screening evaluations;Must haved evidence of MET exon 14 skipping alterations in blood and/or tissue samples. * Adequate bone marrow, hepatic, and renal function * Patients of child bearing potential must agree to take contraception during the study and for 3 months after the last day of treatment * Signed Informed Consent Form Exclusion Criteria: * Prior or current treatment with the type II of c-MET inhibitor or HGF/c-Met antibody therapy * Confirmed ALK or ROS1 rearrangement * Prior treatment with targeting agents (Including EGFR tyrosine kinase inhibitors,VEGFR TKIs,the tpye I of MET TKIs, etc.) within 14 days or 5 half-life * Prior treatment with anticancer agents (Including cytotoxic chemotherapy,radiotherapy, immunotherapy etc.) within 4 weeks * Brain/meninges metastases unless asymptomatic, stable and not requiring steroids for maintenance * History of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease, radiological documentation of idiopathic pulmonary fibrosis at baseline; uncontrolled pleural effusion/pericardial effusion * Any evidence of severe or uncontrolled systemic diseases, including CTCAE 2 or higher active infection, unstable angina pectoris, congestive cardiac failure and severe liver/renal or metabolic disease * Active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV) * History of organ transplant; had surgery or severe injury within 4 weeks * Uncontrolled hypertension(Systolic blood pressure≥160mmHg and/or diastolic blood pressure≥100mmHg ) * Patients unable to swallow orally administered medication, prior surgical procedures affecting absorption. * Pregnant (positive pregnancy test) or lactating women
References
Publications (1)
- DERIVEDHu X, Cui X, Wang Z, Liu Y, Luo Y, Zhong W, Zhao H, Yao M, Jiang D, Wang M, Chen M, Zheng X, Ding L, Wang Y, Yuan X, Wu P, Hu B, Han X, Shi Y. Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study. BMC Cancer. 2023 Apr 11;23(1):331. doi: 10.1186/s12885-022-10500-y. PMID 37041472